Laurence Klotz, MD, FRCSC

University of Toronto

Toronto, Ontario, Canada

Laurence Klotz, MD, FRCSC, is a professor of surgery at the University of Toronto and the Sunnybrook Chair of Prostate Cancer Research. Dr. Klotz was the founding editor-in-chief of both the Canadian Journal of Urology and the Canadian Urology Association Journal (CUAJ), and he is now editor emeritus of the CUAJ. Dr. Klotz obtained his medical degree and completed his residency at the University of Toronto. He was also a uro-oncology fellow at Memorial Sloan Kettering Cancer Center in New York.

Dr. Klotz has 550 peer review publications and eight books. He coined the phrase “active surveillance” and successfully championed this approach for men with favorable-risk prostate cancer against substantial resistance. He was the associate editor of the Journal of Urology, responsible for prostate cancer, for eight years. Dr. Klotz received the Queen’s Jubilee Medal for outstanding public service, the University of Toronto's Lister Prize, the Society of Urologic Oncology’s SUO Medal, the American Urological Association’s Richard Williams Award, the University of Toronto's Lifetime Achievement Award, the Canadian Urological Association Lifetime Achievement Award, and the Harold Warwick Award from the Canadian Cancer Society for “outstanding contributions to cancer control.” In 2015 he was inducted as a Member of the Order of Canada, Canada’s highest civilian award.

Disclosures:

Research Support: Sanofi-Aventis, AbbVie, Exact Imaging
Honorarium Recipient: AstraZeneca, TerSera, Sanofi-Aventis
Consultant: miR Scientific

Talks by Laurence Klotz, MD, FRCSC

MicroRNA Expression Profiles Identify Clinically Significant Prostate Cancer

Posted by Laurence Klotz, MD, FRCSC | Apr 2019

Laurence Klotz, MD, discusses a liquid biopsy urine test that uses microRNA expression profiles to identify clinically significant prostate cancer in patients. He emphasizes the ease and efficiency of the technology, in addition to its high degree of sensitivity and specificity.

Using High Resolution Micro-Ultrasound for Prostate Biopsies for Active Surveillance

Posted by Laurence Klotz, MD, FRCSC | Mar 2019

Laurence Klotz, MD, discusses the limitations of multiparametric MRI (mpMRI) targeted prostate biopsy, especially in the active surveillance setting, and how a novel 29 MHz high resolution micro-ultrasound technology could be an improved alternative. Additionally, he describes his experience with this technology at his institution.

Minimizing Morbidity and Maximizing Outcomes with ADT

Posted by Laurence Klotz, MD, FRCSC | Aug 2018

Laurence Klotz, MD, FRCSC, discusses causes of adverse effects of androgen deprivation therapy (ADT) treatment for prostate cancer and approaches to reducing these side effects. Specifically, Dr. Klotz advises physicians about patient counseling, prescribing innocuous drugs like bisphosphonates and metformin, targeting the adrenal pathway, and utilizing intermittent ADT.

Active Surveillance: From Biology to Bedside Who fails, why, and how can we prevent this?

Posted by Laurence Klotz, MD, FRCSC | Mar 2018

Dr. Laurence Klotz, MD, argues that active surveillance should continue to be a standard of care for prostate cancer, as long as the urological community takes steps to improve screening methods and reduce overdiagnosis.

What Are Best Risk Stratification Tools When Placing Patient on Active Surveillance?

Posted by Laurence Klotz, MD, FRCSC | Oct 2017

Laurence Klotz, MD, Sunnybrook Health Sciences Centre, Toronto, Ontario, discusses the types of...